CRISPR director buys 20,000 shares at $57.03

CRISPR Therapeutics director Douglas A. Treco reported buying common shares of the company.

Accepted by SEC EDGAR 08/08/2025 - 04:06 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CRISPR Therapeutics director Douglas A. Treco reported buying common shares of the company. On August 6, 2025, he made an open-market purchase of 20,000 common shares at a weighted average price of $57.03 per share. Following this transaction, he directly owns 22,000 common shares of CRISPR Therapeutics.

Insider Trade Summary

Net Buyer: 20,000 shares

Net Buy 1 txn

Insider Treco Douglas A

Role Director

Bought 20,000 shs ($1.14M)

Increase in Position 1000.0%

Type	Security	Shares	Price	Value
Purchase	Common Shares	20,000	$57.03	$1.14M

Holdings After Transaction: Common Shares — 22,000 shares (Direct)

Holdings Before and After: Common Shares, 2,000 to 22,000 shares (Direct)

Footnotes (2)

1. F1. Open market purchase of shares in accordance with Issuer's trading policies.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.92 to $57.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CRISPR Therapeutics (CRSP) report for Douglas A. Treco?

CRISPR Therapeutics director Douglas A. Treco reported an open-market purchase of 20,000 common shares. The transaction occurred on August 6, 2025 and reflects a direct increase in his equity position in the company to 22,000 common shares.

How many CRISPR Therapeutics (CRSP) shares did Douglas A. Treco buy and at what price?

Douglas A. Treco bought 20,000 CRISPR Therapeutics common shares in an open-market transaction. The weighted average purchase price was $57.03 per share, based on multiple trades within a disclosed intraday price range.

What is Douglas A. Treco’s total CRISPR Therapeutics (CRSP) ownership after this Form 4?

After the reported transaction, Douglas A. Treco directly owns 22,000 CRISPR Therapeutics common shares. This total reflects the addition of 20,000 shares purchased in the open market on August 6, 2025 under the company’s trading policies.

Was the CRISPR Therapeutics (CRSP) insider transaction an open-market trade?

Yes. The filing states that Douglas A. Treco’s transaction was an open-market purchase conducted in accordance with CRISPR Therapeutics’ trading policies. Such trades occur on the public market at prevailing prices, rather than through private or option-related transactions.

What price range is associated with Douglas A. Treco’s CRISPR Therapeutics (CRSP) share purchase?

The weighted average price reported was $57.03 per share. Footnote disclosure explains that individual trades occurred in multiple transactions at prices ranging from $56.92 to $57.16, with full breakdowns available upon request to the company or regulators.

What role does Douglas A. Treco hold at CRISPR Therapeutics (CRSP)?

Douglas A. Treco is identified as a director of CRISPR Therapeutics. His Form 4 filing reflects a personal open-market purchase of common shares, increasing his directly held stake in the company to 22,000 shares following the reported transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Treco Douglas A

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MA 02127

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/06/2025		P(1)		20,000	A	$57.03(2)	22,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Open market purchase of shares in accordance with Issuer's trading policies.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.92 to $57.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.